CYP17 promotor polymorphism and ovarian cancer risk

International Journal of Cancer

Volumn 89, Issue 2, 2000, Pages 436-439

  Spurdle, Amanda B ^a   Chen, Xiaoqing ^a   Abbazadegan, Mohammed ^b   Martin, Nicholas ^a   Khoo, Soo Keat ^a   Hurst, Terry ^a   Ward, Bruce ^a   Webb, Penelope M ^a   Chenevix Trench, Georgia ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 17; CYTOCHROME P450 ISOENZYME; UNCLASSIFIED DRUG; STEROID 17ALPHA MONOOXYGENASE;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEIC ACID BASE SUBSTITUTION; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; ADENOCARCINOMA; ALLELE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; OVARY TUMOR; RISK;

ADENOCARCINOMA; ALLELES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK; STEROID 17-ALPHA-HYDROXYLASE;

EID: 0034183322     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000501)86:3<436::aid-ijc21>3.0.co;2-a     Document Type: Article

References (21)

1. AUSTRALIAN INSTITUTE OF HEALTH and WELFARE (AIHW) and AUSTRALASIAN ASSOCIATION OF CANCER REGISTRIES (AACR), Cancer in Australia 1995: Incidence and mortality data for 1995 and selected data for 1996. Australian Institute of Health and Welfare, Canberra (1998).
2. BERCHUCK A., KOHLER M.F., MARKS J.R., WISEMAN R., BOYD J. and BAST R.C., The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol, 170, 246-252 (1994).
3. BERGMAN-JUNGERSTROM M., GENTILE M., LUNDIN A-C., South East Breast Cancer Croup and WINGREN S., Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int. J. Cancer (Pred. Oncol.). 84, 350-353 (1999).
4. BOYD J. and RUBIN S.C., Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol. Oncol., 64, 196-206 (1997).
5. CAREY A.H., WATERWORTH D., PATEL K., WHITE D., LITTLE J., NOVELLI P., FRANKS S. and WILLIAMSON R., Polycystic ovaries and premature male-pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. mol. Genet. 10, 1873-187 (1994).
6. CHENEVIX-TRENCH G., and 19 OTHERS, Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer, 18, 75-83 (1997).
7. DIAMANTI-KANDARAKIS E., BARTZIS M.I., ZAPANTI E.D., SPINA G.G., FILANDRA F.A., TSIANATELLI T.C., BERGIELE A.T., KOULI C.R., Polymorphism T to C (-34bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil. Steril., 71, 431-435 (1999).
8. DUNNING A.M., HEALEY C.S., PHAROAH P.D.P., FOSTER N.A., LIPSCOMBE J.M., REDMAN K.L., EASTON D.F., DAY N.E. and PONDER B.A.J., No association between a polymorphism in the steroid metabolism gene CYP17 and the risk of breast cancer. Brit. J. Cancer. 77, 2045-2047 (1998).
9. FEIGELSON H.S., COETZEE G.A., KOLONEL L.N., ROSS R.K. and HENDERSON B.E., A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res., 57, 1063-1065 (1997).
10. FEIGELSON H.S., SHAMES L.S., PIKE M.C., COETZEE G.A., STANCZYK F.Z. and HENDERSON B.E., Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res.. 58, 585-587 (1998).
11. GHARANI N., WATERWORTH D.M., WILLIAMSON R. and FRANKS S., 5′ Polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J. clin. EndocrinoL. Metab., 81, 4174 (1996).
12. HAIMAN C.A., HANKINSON S.E., SPIEGELMAN D., COLDITZ G.A., WILLETT W.C., SPEIZER F.E., KELSEY K.T. and HUNTER D.J., The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res.. 59,1015-1020 (1999).
13. HEATH A.C., BUCHOLZ K.K., MADDEN P.A., DINWIDDIE S.H., SLUTSKE W.S., BIERUT L.J., STATHAM D.J., DUNNE M.P., WHITFIELD J.B., and MARTIN N.G., Genetic and environmental contributions to alcohol dependence risk in a national twin sample: consistency of findings in women and men. Psychol. Med., 27,1381-1396 (1998).
14. HELZLSOUER K.J., HUANG H-Y., STRICKLAND P.T., HOFFMAN S., ALBERG A.J., COMSTOCK G.W. and BELL D.G., Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol. Biomarkers Prev., 7, 945-949 (1998).
15. ICHIKAWA Y., NISHIDA M., SUZUKI H., YOSHIDA S., TSUNODA H., KUBO T., UCHIDA H., and MIWA M., Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res., 54, 33-35 (1994).
16. NEDELCHEVA-KRISTENSEN V., HARALDSEN E.K., ANDERSON K.B., LONNING P.E., ERIKSTEIN B., KARESEN R., GABRIELSEN O.S., and BØRRESEN-DALE A-L., CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res., 59, 2825-2828 (1999).
17. KVALE G., HEUCH I., NILSSON S. and BERAL V., Reproductive factors and risk of ovarian cancer: a prospective study. Int. J. Cancer, 42, 246-251 (1988).
18. OBATA K., MORLAND S.J., WATSON R.H., HITCHCOCK A., CHENEVIXTRENCH G., THOMAS E.J. and CAMPBELL I.G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res., 58, 2095-2120 (1998).
19. PARAZZINI F., FRANCESCHI S., LA VECCHIA C. and FASOLI M., The epidemiology of ovarian cancer. Gynecol. Oncol., 43, 9-23 (1991).
20. PURDIE D., GREEN A., BAIN C., SISKIND V., WARD B., HACKER N., QUNII M., WRIGHT G., RUSSELL P. and SUSIL B., Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int. J. Cancer, 15, 678-84 (1995).
21. WESTON A., PAN C., BLEIWEISS I.J., KSIESKI H.B., ROY N., MALONEY N. and WOLFF M.S., CYP17 genotype and breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 7, 941-944 (1998).